Molecular Partners to Present MP0712 Data at Three May Oncology Conferences
Molecular Partners will present clinical-stage Radio-DARPin candidate MP0712, targeting DLL3 in small cell lung cancer, at NIH’s SCLC Consortium on May 7, at PEGS Boston on May 13 and at Antibody & Engineering Therapeutics Basel on May 29. These oral presentations detail 212Pb-based targeted radiotherapy data across three major oncology conferences.
1. Presentation Schedule
Molecular Partners will deliver oral presentations on MP0712 at three events: the NIH National Cancer Institute Small Cell Lung Cancer Consortium Meeting in Rockville, MD on May 7 (10:30–10:45 am), the 22nd Annual PEGS Boston in Boston, MA on May 13 (2:40–3:10 pm), and the Antibody & Engineering Therapeutics conference in Basel on May 29 (4:45–5:15 pm).
2. Candidate Profile
MP0712 is a Phase I/II clinical-stage Radio-DARPin therapeutic labeled with 212Pb for targeted alpha radiotherapy against DLL3-expressing small cell lung cancer cells, representing the company’s lead radiopharmaceutical candidate with preclinical and early clinical data supporting its safety and tumor-targeting properties.
3. Strategic Significance
These presentations aim to showcase emerging data on MP0712’s pharmacokinetics, tumor uptake and tolerability, potentially shaping investor expectations and partnership discussions as Molecular Partners advances toward later-stage trials and regulatory interactions.